<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259073</url>
  </required_header>
  <id_info>
    <org_study_id>KMalek</org_study_id>
    <nct_id>NCT04259073</nct_id>
  </id_info>
  <brief_title>Does Pregabalin Improve Post-operative Pain After C-section Delivery</brief_title>
  <official_title>Does Pregabalin Improve Post-operative Pain After C-section Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Universitaire Fattouma Bourguiba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Universitaire Fattouma Bourguiba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregabalin due to its antihyperalgesic effect, has proven its efficacy on neuropathic pain,
      essentially in nociceptive surgeries. Few studies have attempted to identify the utility of
      pregabalin as a premedication before cesarean delivery.

      The investigators aimed to determine whether or not pregabalin as premedication improves
      analgesia post cesarean delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conducted a controlled, randomised, prospective and double-blind trial. One
      hundred thirty eight participants were included, with American Society of Anesthesiologists
      physical status classification of I to II, with pregnancies of at least 36 weeks of gestation
      who were scheduled for elective caesarean delivery under spinal anaesthesia. One hour before
      induction of anaesthesia participants received a capsule containing sugar placebo (placebo
      group), pregabalin 150 mg or pregabalin 300 mg. Data related to surgical history,
      pre-existing medical problems, indications for cesarean and peroperative hemodynamic changes
      were analyzed. The primary outcome was first analgesic request. Secondary outcomes included
      maternal pain scores at rest and during movement, rescue analgesics consumption, sedation,
      nausea, vomiting, pruritus and Apgar scores. All maternal secondary outcome variables were
      recorded 0, 2, 4, 6, 12, 18, and 24 h after delivery. Common side effects linked to
      pregabalin such as somnolence, blurred or abnormal vision, or fetal distress were collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">October 10, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first analgesic request</measure>
    <time_frame>24 hours</time_frame>
    <description>in minutes, the time between the end of the operation to the first demand of analgesics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale (VAS) at rest and movement</measure>
    <time_frame>24 hours</time_frame>
    <description>Checked at hours 2, 4, 6,12,18 and 24 post operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal satisfaction</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured by a Visual Analog Scale, ranging from 0 to 100; 0=not satisfied at all</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal consumption of paracetamol postoperatively</measure>
    <time_frame>24 hours</time_frame>
    <description>grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar scores</measure>
    <time_frame>1 and 5 minutes after birth</time_frame>
    <description>Ranging from 0 to 10; 7 to 10 correspond to an excellent condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Per operative period</time_frame>
    <description>beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive blood pressure</measure>
    <time_frame>Per operative period</time_frame>
    <description>measured in millimeters of mercury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual disturbances</measure>
    <time_frame>24 hours post operatively</time_frame>
    <description>present or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluids administered to the mother per operatively</measure>
    <time_frame>Per operative period</time_frame>
    <description>in milliliters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of ephedrine administered to the mother per operatively</measure>
    <time_frame>Per operative period</time_frame>
    <description>in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramsay score for sedation</measure>
    <time_frame>24 hours post operatively</time_frame>
    <description>Ranging from 1 to 6</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two capsules filled with sugar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P150</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two capsules; one of them containing sugar (like the placebo one), the other is the active drug (pregabalin 150 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P300</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two capsules of pregabalin (150 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 150mg</intervention_name>
    <description>two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section</description>
    <arm_group_label>Group P150</arm_group_label>
    <other_name>P150</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>two capsules filled with sugar ingested orally one hour before cesarean section</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300mg</intervention_name>
    <description>two capsules of pregabalin 150 mg ingested orally one hour before cesarean section</description>
    <arm_group_label>Group P300</arm_group_label>
    <other_name>P300</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists class I or II

          -  single pregnancies at term

          -  under spinal anesthesia

        Exclusion Criteria:

          -  conversion to general anesthesia

          -  post partum hemorrhage requiring specific resuscitation

          -  local anesthetic toxicity

          -  violation of the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malek Khemili, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fattouma Bourguiba Hospital ICU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monastir maternity and neonatology center</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <reference>
    <citation>El Kenany S, El Tahan MR. Effect of preoperative pregabalin on post-caesarean delivery analgesia: a dose-response study. Int J Obstet Anesth. 2016 May;26:24-31. doi: 10.1016/j.ijoa.2015.11.001. Epub 2015 Nov 12.</citation>
    <PMID>26718698</PMID>
  </reference>
  <reference>
    <citation>Felder L, Saccone G, Scuotto S, Monks DT, Carvalho JCA, Zullo F, Berghella V. Perioperative gabapentin and post cesarean pain control: A systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2019 Feb;233:98-106. doi: 10.1016/j.ejogrb.2018.11.026. Epub 2018 Dec 12.</citation>
    <PMID>30583095</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Universitaire Fattouma Bourguiba</investigator_affiliation>
    <investigator_full_name>Khemili Malek</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>pregabalin</keyword>
  <keyword>cesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>principal outcomes measured in the study</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>March 2020 for one year</ipd_time_frame>
    <ipd_access_criteria>after request by mailing</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

